Blog Posts

Philippe Aftimos Discusses ctDNA and Molecular Profiling Guiding Therapy for HR+/HER2- Breast Cancer in the ESMO Daily Reporter

ESMO/LinkedIn

Jun 13, 2025, 03:50

Philippe Aftimos Discusses ctDNA and Molecular Profiling Guiding Therapy for HR+/HER2- Breast Cancer in the ESMO Daily Reporter

ESMO – European Society for Medical Oncology shared a post on LinkedIn:

“Metastatic Breast Cancer: Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations.

Read the opinion by Philippe Aftimos in the ESMO Daily Reporter discussing the results of these positive pivotal randomised trials confirming the important role of Molecular Profiling to guide therapy and the emerging role of ctDNA in the detection and targeting of resistance mechanisms.”

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Blog Posts

OncoDaily

Blog Posts

Philippe Aftimos Discusses ctDNA and Molecular Profiling Guiding Therapy for HR+/HER2- Breast Cancer in the ESMO Daily Reporter